Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treprostinil in pulmonary arterial hypertension
NCT05203510Phase 4Active, not recruiting
- Sponsor
- United Therapeutics Corporation
- Start
- Oct 2022
- Primary completion
- Apr 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by United Therapeutics Corporation. Started Oct 2022; status: active, not recruiting.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05203510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05203510.